A blood test to detect pancreatic cancer early
Official title: BLOOD-BASED PROTEOMIC ASSAY FOR PANCREATIC CANCER DETECTION
Funded at Baylor College of Medicine · NIH-10947204 · Data updated 2026-11-12
This study is working on a new blood test to help find pancreatic cancer earlier and more accurately than the current method, which could lead to better treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 13, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $292,729 |
| NIH project number | 1UH2CA292130-01 |
| Project ID | NIH-10947204 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for pancreatic cancer, such as those with a family history of the disease or specific genetic predispositions.
✕Less likely to help
Patients with advanced pancreatic cancer or those who do not meet the high-risk criteria may not benefit from this research.
What this research studies
This research focuses on developing a blood-based proteomic assay to improve the early detection of pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer that often shows no symptoms until advanced stages. The study aims to validate a mass spectrometry-based assay that has shown promise in outperforming the current standard biomarker, CA19-9, in detecting PDAC. By conducting thorough analytical and clinical validations, the research seeks to refine the assay's accuracy and establish its effectiveness for clinical use, potentially leading to earlier diagnosis and better treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could significantly improve early detection of pancreatic cancer, leading to better survival rates for patients.
How similar studies have gone: Previous research has shown success with mass spectrometry-based methods for cancer biomarker detection, indicating a promising approach for this study.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Chen, Ru — Baylor College of Medicine
- Study coordinator: Chen, Ru
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.